B7-H3 (CD276) and CDH17: Molecular Basis and Development Logic of Dual Targets for Immunity and Delivery in Gastrointestinal Tumors

Author: Senior Product Manager of UA Views：10

This article focuses on two gastrointestinal tumor-associated targets, B7-H3 (CD276) and CDH17, and systematically elaborates the mechanisms by which B7-H3, as a B7 family immune checkpoint molecule, promotes tumor progression through immunosuppressive and non-immune pathways, as well as its broad-spectrum high-expression characteristics. It also analyzes the unique logic by which CDH17, as a 7D-cadherin subtype, establishes selectivity based on the positional difference of "accessible on the tumor surface but inaccessible on the normal surface," and compares the differentiated features of the two in terms of sources of therapeutic window, development modalities, and risk management.

Recent Advances
Product Information

Recent Advances

B7-H3 (CD276) and CDH17: The Molecular Basis and Development Logic of Dual Targets for Immunotherapy and Delivery in Gastrointestinal Tumors

Summary: This article focuses on two targets associated with gastrointestinal tumors, B7-H3 (CD276) and CDH17. It systematically elaborates on the mechanisms by which B7-H3, as an immune checkpoint molecule of the B7 family, promotes tumor progression through immunosuppressive and non-immune pathways, as well as its broad-spectrum high-expression characteristics. It analyzes the unique logic by which CDH17, as a 7D-cadherin subtype, establishes selectivity based on the positional difference of "accessible on the tumor surface, inaccessible on the normal surface," and compares the differentiated features of the two in terms of sources of therapeutic window, development modalities, and risk management.

I. Molecular Localization and Immune Checkpoint Properties of B7-H3 (CD276).

B7-H3 (also known as CD276) is an important immune checkpoint molecule of the B7 family proteins, and its ligand remains unclear. In 2001, B7-H3 was first discovered and identified as a member of the B7 family, confirming that the amino acid homology between B7-H3 and other B7 family members is 20% to 27%. The human B7-H3 gene is located on chromosome 15, encoding 316 amino acids, with a relative molecular weight of 45 to 66 kDa. It is a highly glycosylated type I transmembrane protein composed of an extracellular domain, a transmembrane domain, and a short intracellular domain. B7-H3 has two isoforms: 4IgB7-H3 consists of two tandem repeats of IgV-like and IgC-like domains, while 2IgB7-H3 consists of one pair of IgV-like and IgC-like domains; the major isoform expressed on human immune cells and cancer cells is 4IgB7-H3, whereas mice express only the 2IgB7-H3 isoform. In addition, B7-H3 also includes a soluble form with a molecular weight of approximately 37 kDa, which plays a negative regulatory role in T cell responses and is significantly elevated in the serum of cancer patients. B7-H3 is highly expressed in cancer cells and helps cancer cells evade surveillance by cytotoxic T cells and natural killer cells, participating in tumor proliferation, metastasis, and treatment resistance, leading to poor patient prognosis. Therefore, it is a very promising anti-tumor therapeutic target.

II. Expression Distribution of B7-H3 and Its Dual Immune/Non-Immune Tumor-Promoting Mechanisms.

B7-H3 is only lowly expressed or not expressed in a few normal tissues, mainly on the surface of adipocyte progenitor cells, fibroblasts, endothelial cells, osteoblasts, and other cells, with weak staining observed in liver, prostate, uterus, and adrenal gland tissues. In contrast, it is highly expressed in various malignant tumors and activated tumor-infiltrating immune cells: high expression has been detected in lung cancer, breast cancer, prostate cancer, esophageal cancer, ovarian cancer, hepatocellular carcinoma, and other tumor tissues, with a comprehensive positive rate of up to 60%, and high expression is also present on stromal fibroblasts and tumor-associated vasculature; compared with tumor cells, B7-H3 is expressed at even higher levels in cancer stem cells.

In the immune pathway, B7-H3 inhibits the proliferation of CD4-positive and CD8-positive T cells, reduces the production of IL-2 and IFN-γ, and suppresses the activity of NK cells, macrophages, neutrophils, and dendritic cells, inhibiting the secretion of perforin and granzyme B, while promoting the production of IL-10 and TGF-β1 to facilitate the formation of an immunosuppressive microenvironment. In non-immune pathways, B7-H3 participates in cancer cell invasion by activating the PI3K/AKT pathway, upregulates TLR4 expression and inhibits NF-κB to promote IL-8 and VEGF expression, promotes the Ras/Raf/MEK/MAPK pathway to reduce chemosensitivity, upregulates the JAK2/STAT3 pathway to activate apoptosis inhibitors, and promotes glycolysis and lactate increase through reactive oxygen species-mediated HIF1α stabilization. These mechanisms together constitute the complete picture of the tumor-promoting effects of B7-H3.

III. Molecular Structure and Subtype Classification of CDH17.

CDH17, full name Cadherin-17, also known as LI-cadherin, belongs to the 7D-cadherin subtype within the cadherin superfamily, with its gene located at 8q22.1. It differs markedly from classical cadherins such as E-cadherin and N-cadherin: classical cadherins typically have 5 cadherin repeats extracellularly and a longer intracellular tail that can connect to the cytoskeleton through β-catenin/α-catenin; CDH17 has 7 cadherin repeats extracellularly and an intracellular region of only about 18 to 20 amino acids, with almost no classical catenin-binding domain. This means that it does not follow the typical adhesion signaling axis and affects tumor behavior more through positional exposure, cell adhesion environment, integrin interactions, and other means; it is also considered to have proton-dependent oligopeptide transporter function.

IV. The Core Target Logic of CDH17: Positional Difference Rather Than Expression Difference.

The most remarkable aspect of CDH17 is not that it is expressed only in tumors, but that its "degree of exposure" differs between normal tissues and tumor tissues. In normal tissues, CDH17 is mainly expressed in the small intestine and colonic epithelium, with expression also in pancreatic ductal epithelium; the stomach and liver usually show weak or almost no expression in adult tissues. More importantly, it is located on the basolateral membrane of intestinal epithelial cells, blocked on the "inner side" by tight junctions, so antibodies and ADCs in the bloodstream cannot easily access it under normal conditions. In tumors, cell polarity is lost, and CDH17 flips from the "lateral seam" to the cell surface, becoming an accessible membrane antigen. The positive rate in colorectal cancer is very high, reaching over 90% in some cohorts; positivity is also seen in gastric cancer/gastroesophageal junction cancer, pancreatic cancer, cholangiocarcinoma, esophageal adenocarcinoma, and others. In one sentence: the selectivity of CDH17 comes from the positional difference of "accessible on the tumor surface, inaccessible on the normal surface."

V. Functional Positioning of CDH17 in Tumor Promotion and Its Development Paradigm.

CDH17 is indeed not merely a passive marker. Studies have shown that it can promote proliferation and anti-apoptosis through the Wnt/β-catenin pathway, and is associated with integrin α2β1 and other pathways, participating in migration, invasion, and liver metastasis. But a more accurate statement is: it is a tumor promotion-related adhesion molecule, not a typical high-frequency driver mutation like EGFR or KRAS. Therefore, simply using a monoclonal antibody to "block function" often yields limited efficacy; the more mainstream approach is to treat CDH17 as a delivery channel, attaching toxins, T cells, or apoptotic signals. Its selectivity comes from physical barriers rather than complete tissue specificity. Once the barrier is compromised, on-target intestinal toxicity may emerge. Therefore, this target is not a "broad-spectrum, wide therapeutic window, push the dose with eyes closed" blockbuster logic, but rather a delicate game of molecular engineering, indication selection, and dose positioning.

VI. Differentiated Comparison and Synergistic Value of the Dual Targets.

Although B7-H3 and CDH17 both belong to gastrointestinal tumor-related targets, their sources of therapeutic window are entirely different: B7-H3 relies on expression level differences——low expression in normal tissues, high expression in tumor tissues, with a comprehensive positive rate of 60% and coverage of stroma and vasculature; CDH17 relies on physical barrier differences——expressed in normal tissues but shielded by tight junctions, and exposed in tumor tissues due to loss of polarity. This difference determines the division of labor between the two in development modalities: the broad-spectrum high expression of B7-H3 makes it more suitable as a target for immune checkpoint blockade and ADCs, and its stromal and vascular expression also provides the possibility of indirectly killing B7-H3-negative tumor cells; the barrier-type selectivity of CDH17 relies more on dose positioning and indication selection, making it suitable as a precision delivery channel. The two may form a complement in gastrointestinal tumors——one releasing inhibition at the immune microenvironment level, and the other achieving precision killing at the cell surface delivery level.

VII. Conclusion.

As two targets in the gastrointestinal tumor field with distinctly different mechanisms yet equally high attention, B7-H3 and CDH17 represent two different target logics: expression-type selectivity and barrier-type selectivity, respectively. B7-H3, with its comprehensive positive rate of up to 60% in various malignant tumors as well as stroma and vasculature, and its mechanisms of dually driving tumor progression through immunosuppressive and non-immune pathways, has become a broad-spectrum target for immune checkpoint blockade and ADC development; CDH17, with its unique structure of 7 extracellular cadherin repeats and a short intracellular tail, as well as its positional-difference selectivity of "accessible on the tumor surface, inaccessible on the normal surface," has become a precision delivery channel requiring fine dose博弈. Their differentiated features in sources of therapeutic window, development modalities, and risk management jointly enrich the strategic space for targeted therapy of gastrointestinal tumors. UniAI provides B7-H3/CD276 His Tag Protein, Cynomolgus and CDH17/LI-cadherin His Tag Protein, Human, respectively. The former is suitable for binding activity analysis of B7-H3 with targeted antibodies and species cross-reactivity evaluation, in vitro screening of B7-H3-targeted ADCs and bispecific antibodies, and standard preparation in preclinical toxicology evaluation; the latter is suitable for binding activity analysis of CDH17 with targeted antibodies and ADC molecules, research on cell adhesion mechanisms mediated by the cadherin repeat domains of CDH17, and in vitro evaluation of antibody-drug conjugates and CAR-T therapies targeting CDH17, among other application scenarios.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next